Magyar Telekom Select Mavenir’s Converged Packet Core
17.11.2022 10:00:00 EET | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, announce the selection by Magyar Telekom, the leading Hungarian telecommunications service provider, and a subsidiary of Deutsche Telekom, to deploy a cloud-native containerized Converged Packet Core.
Magyar Telekom will use Deutsche Telekom’s locally deployed private cloud solution. Mavenir’s containerized converged packet core will lay the foundation for quickly and easily deploying new enterprise applications and services, taking advantage of 5G features such as low latency and network slicing.
Laszlo Boka, Platform and Core Services Tribe Lead at Magyar Telekom said: “It was important for us to partner with a software provider that could deliver on three main fronts: a Converged Packet Core to support all access technology integration from 2G to 5G, an open architecture that could run on our specified hardware and software platforms, and seamless integration with third-party network functions. Mavenir is a great candidate for us to provide on all three fronts, and we look forward to what the future will bring.”
Mavenir’s 5G Core solution is part of its cloud-native MAVcore portfolio based on an open architecture that offers easy scaling of applications and services, hardware decoupling, agility, portability, and cloud-native resilience.
Key attributes include:
- Open Architecture : uses Deutsche Telekom-defined hardware and a Kubernetes-based platform.
- Network slicing with dedicated control and user plane network functions for meeting strict service level agreements.
- Cloud-native design : a fully containerized solution based on stateless microservice architecture that allows better resiliency and faster recovery in the event of network failures. It also enables the easy onboarding of users on Deutsche Telekom Containers-as-a-Service (CaaS).
- Third-party vendor network function (NF) integration - integrated with multiple third-party vendors, including 4G and 5G access networks (eNodeBs and gNodeBs) and subscriber and policy management functions.
- Converged architecture : Supports 2G, 3G, 4G, 5G non-standalone (NSA), and 5G standalone (SA) modes and enables all access technologies to run on a common cloud-native platform provided by Deutsche Telekom.
Ashok Khuntia, President for Core Networks at Mavenir, said, “Working with Mobile Network Operators globally, we’ve created an agile software delivery process that accommodates specific integration and feature requirements. Integrating Mavenir’s Converged Packet Core into Magyar Telekom’s existing network will enable a fully automated network with the reliability, scale and flexibility to deliver innovative services. Mavenir is pleased to continue to expand our relationship across the Deutsche Telekom subsidiary accounts in Europe.”
About Magyar Telekom:
Magyar Telekom is Hungary’s largest telecommunication operator, it was established in 1991. It provides a full range of telecommunications and infocommunications (ICT) services including fixed line and mobile telephony, data transmission and non-voice as well as IT and systems integration services. Magyar Telekom is the majority owner of Makedonski Telekom, the leading fixed line and mobile operator in the Republic of North Macedonia. Magyar Telekom’s majority shareholder (61.39%) is Deutsche Telekom Europe B.V., fully owned by Deutsche Telekom AG. www.telekom.hu
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005128/en/
Contact information
Magyar Telekom PR Contact:
sajto@telekom.hu
Mavenir PR Contact:
PR@mavenir.com
Maryvonne Tubb (US)
Emmanuela Spiteri (EMEA)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom